Literature DB >> 11401436

Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family.

A Scorilas1, L Kyriakopoulou, G M Yousef, L K Ashworth, A Kwamie, E P Diamandis.   

Abstract

Members of the Bcl-2 family of apoptosis-regulating proteins contain at least one of the four evolutionarily conserved domains, termed BH1, BH2, BH3, or BH4. Here, we report the identification, cloning, physical mapping, and expression pattern of BCL2L12, a novel gene that encodes a BCL2-like proline-rich protein. Proline-rich sites have been shown to interact with Src homology region 3 (SH3) domains of several tyrosine kinases, mediating their oncogenic potential. This new gene maps to chromosome 19q13.3 and is located between the IRF3 and the PRMT1/HRMT1L2 genes, close to the RRAS gene. BCL2L12 is composed of seven coding exons and six intervening introns, spanning a genomic area of 8.8 kb. All of the exon-intron splice sites conform to the consensus sequence for eukaryotic splice sites. The BCL2L12 protein is composed of 334 amino acids, with a calculated molecular mass of 36.8 kDa and an isoelectric point of 9.45. The BCL2L12 protein contains one BH2 homology domain, one proline-rich region similar to the TC21 protein and, five consensus PXXP tetrapeptide sequences. BCL2L12 is expressed mainly in breast, thymus, prostate, fetal liver, colon, placenta, pancreas, small intestine, spinal cord, kidney, and bone marrow and to a lesser extent in many other tissues. We also identified one splice variant of BCL2L12 that is primarily expressed in skeletal muscle. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401436     DOI: 10.1006/geno.2000.6455

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  32 in total

1.  Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.

Authors:  Emmanuel I Papadopoulos; George M Yousef; Andreas Scorilas
Journal:  Tumour Biol       Date:  2015-04-02

2.  A genome-wide study of dual coding regions in human alternatively spliced genes.

Authors:  Han Liang; Laura F Landweber
Journal:  Genome Res       Date:  2005-12-19       Impact factor: 9.043

3.  BCL2L12A localizes to the cell nucleus and induces growth inhibition through G2/M arrest in CHO cells.

Authors:  Yi Hong; Junwu Yang; Yayun Chi; Wenzong Wang; Weibing Wu; Xiaojing Yun; Xiangfei Kong; Jianxin Gu
Journal:  Mol Cell Biochem       Date:  2010-01       Impact factor: 3.396

4.  The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker.

Authors:  Sotirios G Papageorgiou; Christos K Kontos; Vassiliki Pappa; Hellinida Thomadaki; Frida Kontsioti; John Dervenoulas; Efstathios Papageorgiou; Theofanis Economopoulos; Andreas Scorilas
Journal:  Oncologist       Date:  2011-07-07

5.  Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma.

Authors:  Alexander H Stegh; Hyunggee Kim; Robert M Bachoo; Kristin L Forloney; Jean Zhang; Harald Schulze; Kevin Park; Gregory J Hannon; Junying Yuan; David N Louis; Ronald A DePinho; Lynda Chin
Journal:  Genes Dev       Date:  2007-01-01       Impact factor: 11.361

Review 6.  Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma.

Authors:  Alexander H Stegh; Ronald A DePinho
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

7.  Predictive genetic markers of coagulation, inflammation and apoptosis in Perthes disease—Serbian experience.

Authors:  Sanja Srzentić; Gordana Nikčević; Duško Spasovski; Zoran Baščarević; Zorica Živković; Zorica Terzic-Šupić; Dragana Matanović; Valentina Djordjević; Sonja Pavlović; Vesna Spasovski
Journal:  Eur J Pediatr       Date:  2015-03-11       Impact factor: 3.183

8.  Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers.

Authors:  Teodora Karan-Djurasevic; Vuk Palibrk; Branka Zukic; Vesna Spasovski; Irena Glumac; Milica Colovic; Natasa Colovic; Vladimir Jurisic; Andreas Scorilas; Sonja Pavlovic; Natasa Tosic
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

9.  Cell type-dependent proapoptotic role of Bcl2L12 revealed by a mutation concomitant with the disruption of the juxtaposed Irf3 gene.

Authors:  Akira Nakajima; Keishiro Nishimura; Yukana Nakaima; Tomohiko Oh; Shigeru Noguchi; Tadatsugu Taniguchi; Tomohiko Tamura
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-17       Impact factor: 11.205

10.  Cisplatin downregulates BCL2L12, a novel apoptosis-related gene, in glioblastoma cells.

Authors:  Mahdieh Sadat Taghavi; Azim Akbarzadeh; Reza Mahdian; Kayhan Azadmanesh; Gholamreza Javadi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-05-25       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.